Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Seroprevalence of the Anti-SARS-CoV-2 Antibodies in Kidney Transplant Recipients in Severely Affected Region

NCT04874740 is registered in ClinicalTrials.gov with University Hospital Ostrava as lead sponsor.

NCT NCT04874740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04874740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Seroprevalence of the Anti-SARS-CoV-2 Antibodies in Kidney Transplant Recipients in Severely Affected Region
Lead sponsor
University Hospital Ostrava
Phase
Observational
Overall status
Completed
Start date
April 30, 2021
Completion date
October 30, 2022
Enrollment
300 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pandemic, transplantation, kidney